Rotigotine Transdermal Patch in Parkinson's Disease: A Systematic Review and Meta-Analysis

PLoS ONE

Volumn 8, Issue 7, 2013, Pages

  Zhou, Chang Qing ^a   Li, Shan Shan ^a   Chen, Zhong Mei ^a   Li, Feng Qun ^a   Lei, Peng ^a   Peng, Guo Guang ^a  

^a THE FIRST AFFILIATED HOSPITAL OF CHONGQING MEDICAL UNIVERSITY   (China)

Author keywords

[No Author keywords available]

Indexed keywords

LEVODOPA; PLACEBO; ROTIGOTINE;

APPLICATION SITE REACTION; ARTICLE; BACKACHE; CONSTIPATION; DAILY LIFE ACTIVITY SCORE; DIARRHEA; DISEASE ASSOCIATION; DIZZINESS; DRUG EFFICACY; DRUG INDUCED HEADACHE; DRUG SAFETY; DRUG TOLERABILITY; DRUG WITHDRAWAL; DYSKINESIA; ERYTHEMA; HUMAN; INSOMNIA; META ANALYSIS; MOTOR SUBTOTAL SCORE; NAUSEA; PARKINSON DISEASE; PRURITUS; RANDOMIZED CONTROLLED TRIAL (TOPIC); SCORING SYSTEM; SOMNOLENCE; SYSTEMATIC REVIEW; TRANSDERMAL PATCH; UNIFIED PARKINSON DISEASE RATING SCALE; VOMITING;

DOPAMINE AGONISTS; HUMANS; PARKINSON DISEASE; PLACEBOS; RANDOMIZED CONTROLLED TRIALS AS TOPIC; TETRAHYDRONAPHTHALENES; THIOPHENES; TRANSDERMAL PATCH; TREATMENT OUTCOME;

EID: 84880761774     PISSN: None     EISSN: 19326203     Source Type: Journal    
DOI: 10.1371/journal.pone.0069738     Document Type: Article

References (32)

1. Ferrer I, Martinez A, Blanco R, Dalfó E, Carmona M, (2011) Neuropathology of sporadic Parkinson disease before the appearance of parkinsonism: preclinical Parkinson disease. J Neural Transm 118: 821-839.
2. Zhang ZX, Roman GC, Hong Z, Wu CB, Qu QM, et al. (2005) Parkinson's disease in China: prevalence in Beijing, Xian, and Shanghai. Lancet 365: 595-597.
3. Olanow CW, Agid Y, Mizuno Y, Albanese A, Bonuccelli U, et al. (2004) Levodopa in the treatment of Parkinson's disease: current controversies. Mov Disord 19: 997-1005.
4. Goetz CG, Poewe W, Rascol O, Sampaio C, (2005) Evidence-based medical review update: pharmacological and surgical treatments of Parkinson's disease: 2001 to 2004. Mov Disord 20: 523-539.
5. Holloway RG, Shoulson I, Fahn S, Kieburtz K, Lang A, et al. (2004) Pramipexole vs levodopa as initial treatment for Parkinson's disease: a 4-year randomized controlled trial. Arch Neurol 61: 1044-1053.
6. Rascol O, Brooks DJ, Korczyn AD, De Deyn PP, Clarke CE, et al. (2000) A five-year study of the incidence of dyskinesia in patients with early Parkinson's disease who were treated with ropinirole or levodopa. N Engl J Med 342: 1484-1491.
7. Lees AJ, Katzenschlager R, Head J, Ben-Shlomo Y, (2001) Ten-year follow-up of three different initial treatments in de-novo PD. a randomized trial. Neurology 57: 1687-1694.
8. Schrag A, Quinn N, (2000) Dyskinesias and motor fluctuations in Parkinson's disease. A community-based study. Brain 123: 2297-2305.
9. Poewe W, Wenning G (2002) Levodopa in Parkinson's disease: mechanisms of action and pathophysiology of late failure. In: Jankovic J, Tolosa E, editors. Parkinson's disease and movement disorders. Philadelphia: Lippincott Williams & Wilkins. 104-115.
10. Jenner P, (2005) A novel dopamine agonist for the transdermal treatment of Parkinson's disease. Neurology 65: S3-5.
11. Metman LV, Gillespie M, Farmer C, Bibbiani F, Konitsiotis S, et al. (2001) Continuous transdermal dopaminergic stimulation in advanced Parkinson's disease. Clin Neuropharmacol 24: 163-169.
12. Braun M, Cawello W, Poole K, Horstmann R, (2005) Steady-state pharmacokinetics of rotigotine in patients with early-stage Parkinson's disease. Eur J Neurol 12: 96.
13. Elshoff JP, Braun M, Andreas JO, Middle M, Cawello W, (2012) Steady-state plasma concentration profile of transdermal rotigotine: an integrated analysis of three, open-label, randomized, phase I multiple dose studies. Clin Ther 34: 966-978.
14. Schnitzler A, Leffers KW, Hack HJ, (2010) High compliance with rotigotine transdermal patch in the treatment of idiopathic Parkinson's disease. Parkinsonism Relat Disord 16: 513-516.
15. Wüllner U, Kassubek J, Odin P, Schwarz M, Naumann M, et al. (2010) Transdermal rotigotine for the perioperative management of Parkinson's disease. J Neural Transm 117: 855-859.
16. Quinn N, SP511 Investigators (2001) Rotigotine transdermal delivery system (TDS) (SPM962)- A multi-center, double-blind, randomized, placebo-controlled trial to assess the safety and efficacy of rotigotine TDS in patients with advances Parkinson's Disease. Parkinsonism Relat Disord 7: S66.
17. Sanford M, Scott LJ, (2011) Rotigotine Transdermal Patch A Review of its Use in the Treatment of Parkinson's Disease. CNS Drugs 25: 699-719.
18. Jadad AR, Moore A, Carroll D, Jenkinson C, Reynolds DJM, et al. (1996) Assessing the quality of reports of randomized clinical trials: is blinding necessary? Control Clin Trials 17: 1-12.
19. The Parkinson Study Group (2003) A controlled trial of rotigotine monotherapy in early Parkinson's disease. Arch. Neurol 60: 1721-1728.
20. Jankovic J, Watts RL, Martin W, Boroojerdi B, (2007) Transdermal rotigotine: double-blind, placebo-controlled trial in Parkinson disease. Arch. Neurol 64: 676-682.
21. Giladi N, Boroojerdi B, Korczyn AD, Burn DJ, Clarke CE, (2007) Rotigotine transdermal patch in early Parkinson's disease: a randomized, double-blind, controlled study versus placebo and ropinirole. Mov Disord 22: 2398-2404.
22. LeWitt PA, Lyons KE, Pahwa R, (2007) Advanced Parkinson disease treated with rotigotine transdermal system PREFER Study. Neurology 68: 1262-1267.
23. Poewe WH, Rascol O, Quinn N, Tolosa E, Oertel WH, et al. (2007) Efficacy of pramipexole and transdermal rotigotine in advanced Parkinson's disease: a double-blind, double-dummy, randomised controlled trial. Lancet Neurol 6: 513-520.
24. Trenkwalder C, Kies B, Rudzinska M, Fine J, Nikl J, et al. (2011) Rotigotine effects on early morning motor function and sleep in Parkinson's disease: a double-blind, randomized, placebo-controlled study (RECOVER). Mov Disord 26: 90-99.
25. Baker WL, Silver D, White CM, Kluger J, Aberle J, et al. (2009) Dopamine agonists in the treatment of early Parkinson's disease: A meta-analysis. Parkinsonism Relat Disord 15: 287-294.
26. Talati R, Baker WL, Patel AA, Reinhart K, Coleman CI, (2009) Adding a dopamine agonist to preexisting levodopa therapy vs. levodopa therapy alone in advanced Parkinson's disease: a meta analysis. Int J Clin Pract 63: 613-623.
27. Hauser RA, Auinger P, (2011) Parkinson Study Group (2011) Determination of minimal clinically important change in early and advanced Parkinson's disease. Mov Disord 26: 813-818.
28. Talati R, Reinhart K, Baker W, White CM, Coleman CI, (2009) Pharmacologic treatment of advanced Parkinson's disease: A meta-analysis of COMT inhibitors and MAO-B inhibitors. Parkinsonism Relat Disord 15: 500-505.
29. Oertel W, LeWitt P, Giladi N, Ghys L, Grieger F, et al. (2013) Treatment of patients with early and advanced Parkinson's disease with rotigotine transdermal system: Age-relationship to safety and tolerability. Parkinsonism Relat Disord 19: 37-42.
30. Kulisevsky J, Pagonabarraga J, (2010) Tolerability and safety of ropinirole versus other dopamine agonists and levodopa in the treatment of Parkinson's disease: meta-analysis of randomized controlled trials. Drug Saf 33: 147-161.
31. Cummings JL, Farlow MR, Meng X, Tekin S, Olin JT, (2010) Rivastigmine transdermal patch skin tolerability: Results of a 1-year clinical trial in patients with mild-to-moderate Alzheimer's disease. Clin Drug Investig 30: 41-49.
32. UCB (2012) Neupro® approved by U.S. FDA for Parkinson's Disease and Restless Legs Syndrome [online]. Available from URL: http://www.ucb.presscentre.com/News/Neupro-approved-by-U-S-FDA-for-Parkinson-s-Disease-and-Restless-Legs-Syndrome-2d6.aspx. Accessed 2012 April 3.